Compare GFS & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFS | KVUE |
|---|---|---|
| Founded | 2009 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Specialty Chemicals |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8B | 34.2B |
| IPO Year | 2017 | 2023 |
| Metric | GFS | KVUE |
|---|---|---|
| Price | $48.96 | $17.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 14 |
| Target Price | ★ $76.00 | $19.50 |
| AVG Volume (30 Days) | 3.3M | ★ 22.6M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | 1.00% | ★ 4.76% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $7.60 | $3.12 |
| Revenue Next Year | $12.52 | $2.38 |
| P/E Ratio | ★ $29.28 | $37.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.02 | $14.02 |
| 52 Week High | $92.55 | $20.13 |
| Indicator | GFS | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 34.40 |
| Support Level | $46.38 | $17.01 |
| Resistance Level | $48.16 | $17.88 |
| Average True Range (ATR) | 1.64 | 0.26 |
| MACD | 0.56 | 0.00 |
| Stochastic Oscillator | 81.17 | 1.92 |
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and has about 13,000 staff.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.